Related Experiment Video

Updated: Oct 29, 2026

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

Influence of pulmonary blood pressure and flow on endothelin-1 production in humans

S Ishikawa1, T Miyauchi, H Ueno

  • 1Department of Pediatric Cardiology, Fukuoka Children's Hospital, Japan.

Journal of Cardiovascular Pharmacology
|January 1, 1995
PubMed

Insights

Endothelin-1 (ET-1) production increases with pulmonary hypertension due to pressure overload but decreases with volume overload in children with congenital heart disease.

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Vascular Biology

Background:

  • Endothelin-1 (ET-1) plays a crucial role in cardiovascular regulation.
  • Understanding ET-1 production in congenital heart disease (CHD) is vital for managing pulmonary circulation.
  • Altered hemodynamics in CHD can impact ET-1 levels.

Purpose of the Study:

  • To investigate the regulation of endothelin-1 (ET-1) production in pediatric patients with congenital heart disease.
  • To determine how different hemodynamic loads (pressure vs. volume overload) affect ET-1 levels.
  • To assess the influence of pulmonary hypertension and congestion on ET-1.

Main Methods:

  • Cardiac catheterization in young patients with CHD (mean age 27 months).
  • Measurement of plasma ET-1 levels in the inferior vena cava using sandwich-enzyme immunoassay.
  • Comparison of ET-1 levels between patient groups (atrial septal defect, ventricular septal defect with PH, pulmonary venous stenosis with PH) and healthy controls.

Main Results:

  • Patients with atrial septal defect (volume overload, no PH) showed significantly lower ET-1 levels than controls.
  • Patients with ventricular septal defect (VSD) and PH (pressure & volume overload) had significantly higher ET-1 levels.
  • Patients with PH and severe pulmonary congestion due to pulmonary venous stenosis (PVS) exhibited even higher ET-1 levels than VSD patients, suggesting ET-1 augmentation by congestion.

Conclusions:

  • ET-1 production is increased by pressure overload to the pulmonary circulation in pediatric CHD.
  • ET-1 production is decreased by volume overload to the pulmonary circulation.
  • Pulmonary congestion may further augment ET-1 production in patients with severe CHD.

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies09:08

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies

Published on: May 24, 2021

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...